

# KINGDOM SAUDI ARABIA NATIONAL ACTION PLAN ON combating ANTIMICROBIAL RESISTANCE

January 2017



# Table of content

Abbreviations and acronyms	3
Foreword	4
Executive summary	5
Introduction	6
Situation analyses and Assessment	7
Country Response	9
Strategic plan	10
Operational plan and budget	18
Monitoring and evaluation plan	35
References	42

# Abbreviations and acronym

AMR	Antimicrobial Resistance
C-DIFF	Clostridium Difficile
CLSI	The Clinical and Laboratory Standards Institute
CRE	Carbapenem-Resistant Enterobacteriaceae
DDD	Defined Daily Dose
DOT	Days of therapy
ESBL	Extended-Spectrum Beta-Lactamases
EUCAST	European Committee for Antimicrobial Susceptibility Testing
FAO	The Food and Agriculture Organization of the United Nations
GLASS	Global Antimicrobial Resistance Surveillance System
GCC-I-C	Gulf Cooperation Council- Center of infection control
GDIPC	General Directorate of Infection Prevention and Control
GHSA	Global Health Security Agenda
GNB	Gram-negative bacteria
HCAIs	Healthcare-Associated Infections
HESN	Healthcare Electronic Surveillance Network
IPC	Infection Prevention Control
KFMC	King Fahd Medical City
KSA	Kingdom of Saudi Arabia
МОН	Ministry of Health
MOE	Ministry of Education
MEWA	Ministry of environment, water, and agriculture
MDROs	Multi-Drug Resistant Organisms
MRSA	Methicillin Resistant Staph Aureus
NGHA	National Guard Health Affairs
NHSN	National Healthcare Safety Network
OIE	World Organization for Animal Health
Saudi FDA	Saudi Food and Drug Administration
US-CDC	United States Center for Disease Control and Prevention
Vet. Clinics	Veterinary Clinics
VRE	Vancomycin-Resistant <i>Enterococci</i>
WHO	World Health Organization

#### **Foreword**

Antimicrobial resistance threatens the advancement in medicine and the ability to respond to the threat of infectious diseases. The complexity of management and care of patients require effective antimicrobial drugs to prevent and treat associated infections with various conditions and especially those with surgeries and receiving chemotherapy. Misuse and overuse of antimicrobials in human medicine and food production have put every nation at risk, and the Kingdom of Saudi Arabia is not an exception. Few replacement products are in the pipeline. Therefore, an immediate action on a global scale is required before we lose such essential agents. Without such action, we are heading towards a post-antibiotic era in which common infections could once again kill. It is suggested that without policies to stop the worrying spread of AMR, today's already large 700,000 deaths every year would become an extremely disturbing 10 million every year, more people than currently die from cancer. Indeed, even at the current rates, it is fair to assume that over one million people will have died from AMR since he started this Review in the summer of 2014. AMR also has a very real economic cost, which will continue to grow if resistance is not tackled. The cost regarding lost global production between now and 2050 would be an enormous 100 trillion USD if we do not act.

Alert to this crisis, the May 2015 World Health Assembly adopted a global action plan on antimicrobial resistance, which outlines five objectives:

To improve awareness and understanding of antimicrobial resistance through effective communication, education, and training

To strengthen the knowledge and evidence base through surveillance and research; to reduce the incidence of infection through effective sanitation, hygiene and transmission prevention measures

To optimize the use of antimicrobial medicines in human and animal health

To develop the economic case for sustainable investment that takes account of the needs of all countries and to increase investment in new drugs, diagnostic tools, vaccines and other interventions.

This action plan for the Kingdom Saudi Arabia to combat antimicrobial resistance has been formulated in the line of the WHO five objectives. It addresses the need for effective "one health" approach involving coordination among numerous national sectors and actors, including human and veterinary medicine, agriculture, finance, environment, and well-informed consumers. Therefore, a large committee of all stakeholders was formed with five technical subcommittees were established to addresses every aspect to contain antimicrobial resistance in the country.

Hail M. Al-Abdely, MD Head, AMR National Committee

## **Executive summary**

World Health Assembly adopted a global action plan in May 2015 on antimicrobial resistance, which outlines five objectives, so, Kingdom Saudi Arabia conjoined National Committee for tackling the antimicrobial resistance representing members from different national organizations and formulated five technical committees to implement the WHO AMR objectives.<sup>1</sup>

The Kingdom Saudi Arabia AMR national action plan highlights the need for effective "one health" approach including human and animal health.

#### The core component of the KSA AMR national action plan consists of:

- 1. Strategic plan (goal and objectives, priories and intervention)
- 2. operational plan (activities, implementation arrangements, time table, responsible entities, detailed budgeting and costing
- 3. Monitoring and evaluation plan (performance indicators, targets and timelines, and data collection and reporting methods)
- 4. The objectives of the plan will be achieved by implementing the following Strategic activities
- 4.3 Improvement the awareness of antimicrobial resistance and promote behavioral change
- 4.4 Studying the pattern of antimicrobial resistance
- 4.5 Implementing Infection control programs
- 4.6 Implementing an antibiotic stewardship program
- 4.7 Study the Economic burden of AMR in human and animal health

#### Introduction

Antimicrobial resistance (AMR) in bacteria is emerging and spreading rapidly worldwide. This phenomenon is nowadays affecting public and animal health dramatically on a global level. Unfortunately, the current dependence on antibiotics - whether to treat, prevent, or stimulate food animal growths - have exponentially increased this resistance. When antibiotics are used, selective pressure is created, and possibly forcing the exposed bacteria to mutate or acquire pieces of DNA to become antibiotic resistant. The selection pressure resulting from the overwhelming use and misuse of antibiotics is exponentially supporting the AMR phenomenon. The multidrug-resistant (MDR) pathogens are spreading rapidly in many parts of the world causing severe medical and economic consequences. It is estimated that at least every 10 minutes a patient dies in the USA or Europe because of fatal infections caused by antibiotic-resistant bacteria <sup>1</sup>

The Goal of the WHO Global action plan is to ensure, for if possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them. In May 2015 World Health Assembly adopted a global action plan on antimicrobial *resistance with five objectives* <sup>1,2</sup>

**Objective 1:** Improve awareness and understanding of antimicrobial resistance through effective communication, education, and training

**Objective 2:** Strengthen the knowledge and evidence base through surveillance and research

**Objective 3:** Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures

**Objective 4:** Optimize the use of antimicrobial medicines in human and animal health

**Objective 5:** Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions

The kingdom Saudi Arabia AMR action plan underscores the need for effective "one health" approach involving coordination among numerous international sectors and actors, including human and veterinary medicine, agriculture, finance, environment, and well-informed consumers. The action plan recognizes and addresses both the variable resources nations must combat antimicrobial resistance and the economic factors that discourage the development of replacement products by the pharmaceutical industry. The objectives of WHO were also adopted by The Kingdom of Saudi Arabia.

## Situational Analysis and Assessment

A literature review of MDR in Gram-negative bacilli (GNB) showed a substantial increase in the rate of carbapenem-resistant GNB in Saudi Arabia over the last decade in comparison with the rates of the 1990s<sup>3</sup>. It also documented the increasing prevalence of extended spectrum beta-lactamase (ESBL) producing isolates from Saudi Arabia, where some institutions had 29% ESBL rates among Escherichia coli (E. coli) and 65% ESBL rates among *Klebsiella pneumoniae* (K. pneumoniae). Thus, these increasing rates have been associated with many reported outbreaks and mortality that ranged between 11-40% <sup>3</sup>

Recent region-wide surveillance studies reported that most of carbapenem-resistant *Enterobacteriaceae* (CRE) from the Gulf Cooperation Council States (GCC) had been found to harbor the carbapenemase-encoding genes blaOXA-48-type, and blaNDM-1.<sup>4</sup> Carbapenem-resistant Acinetobacter baumannii (A. baumannii) (CRAB) from Saudi Arabia have also increased dramatically over the years. A recent study from Riyadh<sup>5</sup> showed that the susceptibilities of A. baumannii to meropenem and imipenem in 2006 ranged between 64-81.2%, while the susceptibility in 2012 ranged between 8.3-11%. Molecular investigation on different CRAB isolates obtained from all the GCC states revealed that many isolates, from different countries, have clustered together, suggesting clonality.<sup>6</sup> The colistin resistant and even pan-drug resistant GNB have already been reported.

A Saudi national surveillance on Gram-positive cocci demonstrated that 32% of Staphylococcus *aureus* (S. aureus) are methicillin-resistant (MRSA), and 33% of Streptococcus pneumoniae are resistant penicillin G and 26% are resistant to erythromycin.<sup>7</sup>

Several factors are associated with the increasing emergence and spread of MDR bacteria in Saudi Arabia. It is evident that the unoptimized use of antibiotics is a major factor for AMR development. A hospital in Riyadh has well demonstrated the overuse of antimicrobial agents from 4 adult ICUs in 2010, where the highest use was meropenem (33.2 defined daily doses [DDD] per 100 bed-days), followed by piperacillintazobactam (16.0 DDD/100 bed-days). On the other hand, the DDD/100 bed-days in 37 ICUs in the United States was 3.75 for carbapenems and 7.08 for antipseudomonal penicillins. Over-the-counter antibiotics without prescription in Saudi community pharmacies is another issue that is driving the improper use of antibiotics. Only one out of 88 pharmacists in Eastern province refused to sell antibiotics without a prescription, and 77.6% of the pharmacies in Riyadh dispensed antibiotics without a prescription

Heavy international travel activities are occurring due to the large population of expatriates and to pilgrimage the Holy cities. A recent study showed that returned travelers from Hajj had acquired MDR A. baumannii and NDM-producing E. coli during the Hajj event. Previous data from 2 major hospitals in Makkah showed that ceftazidime resistance is evident in 24.6% of E. coli, 34.4% of K. pneumoniae, and 52.7% of P. aeruginosa.<sup>8</sup>

Another issue that can contribute to the spread of AMR is the challenges related to the adherence of infection control practices. The hand hygiene compliance rate in a hospital in Makkah in 2011 was 50.3%.

The effectiveness of hand hygiene compliance was well demonstrated in controlling a nosocomial outbreak caused by carbapenem-resistant K. pneumoniae in Riyadh<sup>3</sup>.

There hasn't been a structured national plan on laboratory surveillance and preventive measures to circumvent the ongoing surge in microbial resistance. A survey of 20 MOH laboratories survey done in 2015 has shown that 18 out 20 hospitals reported antibiograms with current CLSI reference. They have AMR policy and quality assurance, it was found that 60% of *staph aureus* were resistant to oxacillin, and 50% of *E Coli* were resistant to 3<sup>rd</sup> generation cephalosporins,60% of *Acinetobacter* resistant to Amikacin AND Colistin 40%). Although detection and reporting happen at the institutional level, but coordination between health institutions was not established. No data exist on incidence, mortality and economic impact. Now through the National AMR program, a systematic approach toward the problem is established in guidance with WHO and GHSA action package.<sup>9</sup>

## **Country Response**

#### Governance

A conjoined National Committee for Tackling the problem of AMR signed with the highest authority (His Excellency the Minister of Health) has been formed with representatives from the following bodies:

#### **Ministry of Health**

- National CDC
- 2. Assistant deputy ministry for preventive medicine (The General Directorate of Infection prevention and control, The General Directorate for Infectious Diseases, Field Epidemiology program)
- 3. The General Directorate of Laboratories and Blood Banks
- 4. National Health Laboratory
- 5. The General Directorate of Pharmaceutical Affairs
- 6. The General Directorate for Hospitals
- 7. The General Directorate for Media and general affairs
- 8. Medical Cities
- 9. The Directorate of Medical Licensing

#### **Governmental non-MOH**

- 1. Ministry of Environment, Water, and Agriculture
- 2. Ministry of Education
- 3. Ministry of Defense- Health Affairs
- 4. Ministry of Interior Health Affairs
- 5. Ministry of National Guard Health Affairs
- **6.** Ministry of Culture and Information
- 7. King Saud University
- 8. King Abdul Aziz City for Science and Technology (KACST)
- 9. King Saud Bin Abdul Aziz University for Health Sciences
- 10. King Faisal Specialist Hospital and Research Center
- 11. Saudi Food and Drug Authority
- **12.** Gulf Cooperation Council Centre for Infection Control
- 13. Central Board for Accreditation of Healthcare Institutions (CBAHI)
- 14. Saudi Commission for Health Specialties

#### Non-Governmental organizations (NGOS)

- 1. The Saudi Society for Medical Microbiology and Infectious Diseases
- 2. The Saudi Society for Pediatric infectious diseases
- 3. The Saudi Society for Sterilization and Infection control

Part I:
Strategic Plan

## **KSA AMR Strategic Plan**

# Global action plan strategic objective 1: Improve awareness and understanding of antimicrobial resistance through effective communication, education, and training

Objective 1	Increase National	Awareness about AMR
Objective 1.	increase ivational	Awareness about Aivik

Strategic interventions	Activities	Milestone
Objective 1. Increase National Avairategic interventions  1.1. Establish an evidence-based communication program targeting the public for both human and animal health	1.1.1 Assess public awareness about AMR and Survey on public awareness of use and misuse of antibiotics. Assign a research team to conduct qualitative (focus group) and quantitative (surveys) data collection. Survey on knowledge and attitude toward use and misuse of Antibiotics in Livestock 1.1.2. Production of Media related materials including documentary on AMR 1.1.3. Awareness campaign during Antimicrobial Awareness Week (November 2016) in response to WHO World Antibiotic Awareness Week from 14- 20 November 2016 with the theme this year "Antibiotics: Handle with Care." The activities include: - Preparation of awareness materials and brochures, Short awareness messages for broadcasting on Twitter and snap chat, Awareness Video " History of war between bacteria and antibiotics" on YouTube, Broadcasting on TV channel and national newspapers to sensitize society about antimicrobial resistance and rationalizing antibiotic use, Attraction of famous	Milestone Oct 2017
	players in Saudi teams to participate in sending the awareness messages, survey study to assess community awareness of antibiotic use.	
	1.1.4. Mainstream media engagement 1.1.5. Applying the tailored interventions 1.1.5.1. Universities carry out direct public engagement campaigns.	

	<ul> <li>1.1.5.2. Award university clubs.</li> <li>1.1.5.3. Work with MOH and launch the Public Health Champion program.</li> <li>1.1.5.4. Work with MOE on national curriculum to include the AMR topic.</li> </ul>	
1.2. Establish an evidence-based public communication program targeting the healthcare providers for both human and animal health	1.2.1 Awareness program will be prepared for health care providers for both in human and animal health	Oct 2017
Objective 2. Improve knowledge o	f AMR and related topics	
2.1. Include AMR and related topics as a core component of professional education, training, certification and development	<ul> <li>2.1.1. AMR and related topics in undergraduate curricula for human health professionals, animal health professionals and food industry and agriculture professionals.</li> <li>2.1.2. AMR E-Learning educational program</li> <li>2.1.3. AMR revised and approved educational programs_in health care facilities</li> </ul>	Oct 2017

Global action plan Strategic Objective 2: Strengthen the knowledge evidence base through surveillance and Research		
Objective 3. Set up a national surveillance system for antimicrobial resistance		
3.1. Establish a national coordination structure for surveillance of AMR.	3.1.1. National coordinating committee with appropriate mandate and terms of reference and a focal point (Lab surveillance technical committee, Dr. Ali Alsomaily)	Jan 2017
3.2. Designate and develop reference microbiology laboratory facilities to coordinate an effective epidemiologically surveillance of antimicrobial resistance	<ul> <li>3.2.1. Seven CAP accredited. Laboratories were designated to collect the antimicrobial resistance data for the last five years. Riyadh: (KAMC-Riyadh, King Faisal Specialist Hospital &amp; Research Center, KFMC, and King Khaled University Hospital); Eastern Province: King Fahd University hospital in Khobar; Western Province: King Abdulaziz University Hospital.</li> <li>3.2.2. Twenty-four MOH laboratories Antibiogram from various regions of the kingdom.</li> </ul>	June 2017

	<ul><li>3.2.3. Determination of KPIs needed from each of the sentinel sites.</li><li>3.2.4. Utilizing Point of care testing</li></ul>	
3.3. AMR surveillance Sentinel sites in human	3.3.1. 12 AMR surveillance Sentinel sites from different regions are selected	March 2017
3.4 AMR Sentinel sites in animal	3.4.1. Six Sentinel sites for surveillance of infections caused by AMR pathogens: Riyadh. Al-Hassa, Al-Dammam Jeddah Assir Al-Kharj 3.4.2. Surveillance for detection of salmonella, campylobacter and total bacterial count in poultry in all regions of Kingdom (2016).	JAN 2017
3.5. Determine the country priority microorganisms with mechanisms of resistance for AMR surveillance and adapt and apply WHO model systems for antimicrobial resistance surveillance (GLASS)	<ul> <li>3.5.1. WHO priority pathogens including (S. aureus, E. coli, K. pneumoniae plus added pathogens of national priority as VRE, Non-Fermentative GNB. Acinetobacter, Pseudomonas)</li> <li>3.5.2. GLASS protocol was endorsed to laboratories during a workshop (10 Labs) and includes age and sites in the upcoming data.</li> </ul>	June 2017
3.6. Establishment of systems IT for	3.6.1. Working on software to link Designated sentinel to	

monitoring antimicrobial and link all sentinel sites to the national center for analysis and reporting.	national lab to improve reporting analysis	June 2017
Objective 4. Build laboratory capac support surveillance activities in bo	city to produce high-quality microbiological data for patient match human and animal sectors	anagement and
4.1. Designate a national reference laboratory for AMR surveillance	4.1.1. The National lab will assume responsibility for AMR lab in the future. Currently, the AMR Sentinel sites labs will perform required AMR testing and reporting	June 2017
4.2. training workshops for microbiologist and laboratory technicians	4.2.1. Plan for series training, workshops will be formulated for Microbiology doctors and lab technicians for all hospitals> 150 beds	June 2017

Global action plan strategic Objective 3: Reduce the incidence of infection through effective sanitation, hygiene and prevention measures		
Objective 5. Establish a national in	fection prevention and control program	
5.1. Create a formal organizational structure to ensure proper development and use of infection prevention and control policies and strategies	<ul> <li>5.1.1. IC Organizational structure has been established</li> <li>5.1.2. Core component has been established and distributed</li> <li>5.1.3. Infection control national manual distributed to all health care regions</li> <li>5.1.4. IC Auditing tool program</li> <li>5.1.5. Hand hygiene campaign</li> </ul>	2017
Objective 6. Introduce infection pr	evention and control program in veterinary settings and anima	al husbandry
6.1. Create a formal organizational structure to ensure proper development and use of infection prevention and control policies and strategies	6.1.1. Write and approve Infection Control Guideline in animal health by KSA MEWA	June 2017
6.2. Include hygiene and infection prevention and control as core	6.2.1. MEWA plans for Infection control training	June 2017

(mandatory) content in training and education of veterinary professionals		
Objective 7 Limit the development	and spread of AMR outside health settings by infection preven	ntion and control
7.1. Promote personal hygiene by social mobilization and behavioral change activities	7.1.1. Estimate knowledge of personal hygiene in different social groups as a basis for the social mobilization campaigns	June 2017

Global action plan strategic Objective 4: Optimize the use of antimicrobial medicines in human and animal health		
Objective 8. Ensure uninterrupted	access to high-quality antimicrobial medicines	
8.1. Strengthen the pharmaceutical supply chain, including the procurement, supply, and management system.	8.1.1. Establish a quality management system for the supply of medicines, covering storage, transport, expiry date, etc.	June 2017
Objective 9. Improve and measure ap	propriate use of antimicrobial agents in health care	
9.1. Create formal antimicrobial stewardship programs in health care facilities	9.1.1. Plan for series training, antimicrobial stewardship programs workshops will be formulated in all healthcare facilities > 150 beds	Dec 2017
9.2. Awareness and Education on stewardship for Healthcare facilities & veterinary practice	9.2.1. Target selected hospitals based on bed capacity from each region of the kingdom:  1- Antibiotic Awareness week  2- Workshops, seminars, case studies, grand rounds, etc.  3-Booklets, brochures, posters, &pocket cards  4- Teleconference or phone consults to hospitals with no ID or Clinical pharmacists to perform ASP  5- Increase awareness of public pharmacist on ASP  9.2.2. To consider standardized educational material or electronic tool	June 2017
9.3. Guidelines and order sets	4.7.1 Development, awareness & Implementation of empiric antimicrobial guidelines for treatment of community & healthcare associated infection to 20 MOH hospitals.	June 2017

		-
	<ul> <li>4.7.2 Integrating those guidelines into electronic health records whenever possible.</li> <li>4.7.3 Standardizing Surgical Antibiotic Prophylaxis through preset order sheets in 20 selected MOH hospitals.</li> </ul>	
9.4. Clinical Care Standards "bundle" implementation	9.4.1. Medium sized (>150 beds) hospitals should apply "MOH- approved" stewardship bundles/ best practices to optimize prescribing practices	Dec 2017
9.5. Mandating Stewardship implementation in all JCI/ CBAHI accredited hospitals	9.5.1. Communicate with CBAHI to include ASP in the requirements for accreditation/ reaccreditation."	June 2017
9.6. Requesting Stewardship Program KPIs on process and outcome	9.6.1. 5 Antibiotics, 5 MDROs: 1- DOT per 1000 patient days 2- Duration of empiric antibiotics therapy more than seven days 3- Prevalence and trend of CDI	April 2017
9.7. Postgraduate education: enrollment requirement for national residency training programs	9.7.1. Communication with Saudi Commission for Health Specialties to add to Infection control module Stewardship component; it can be an online module as a prerequisite for enrollment in all medical, nursing, paramedical, and Pharmacy residency programs."	Jan 2018
9.8. Building Capacity: Training Clinical Pharmacists and ID Fellows	9.8.1. Antimicrobial Stewardship training programs	Jan 2018
9.9. Train the Trainers once a group of certified trained personnel is available	9.9.1. Setting up a training center/ academy in MOH to train trainers in Principles and Practice of Implementation of ASP in Healthcare Settings	Jan 2018
9.10. Antimicrobial Stewardship Research	9.10.1National Point Prevalence Survey on antimicrobial consumption & resistance in line with Global PPS -Multicenter study on the impact of implementation of stewardship on length of stay & cost saving	June 2017
Objective 10. Ensure prudent use o	of antimicrobial agents in terrestrial and aquatic animals and a	griculture
10.1. Restrict use of critically important antimicrobials for human medicine in food production animals	10.1 Ongoing surveillance of antibiotics consumed in food production animals and avoiding the following antimicrobial classes: Quinolones, 3rd and 4th generation cephalosporin antibiotics, macrolides,	Jan 2018

ketolides, and glycopeptides	

needs of all countries, and increase invest	Develop the economic case for sustainable investment that tement in new medicines, diagnostic tools, vaccines and other erch and prepare the economic case for utilization of new medons	interventions
11.1. Economic impact assessment and burden of antimicrobial resistance	<ul><li>11.1.1. Study the cost and economic burden of AMR in Humans.</li><li>11.1.2. Study the cost and economic burden of AMR in animals.</li></ul>	June 2017 Oct 2017

Part II:
Operational plan
and budget

# **Operational plan and budget**

Activity	Unit	Quantity	Date	Location	Responsible entity	Cost (SAR)	Source of funding	Indicator
Strategic intervention 1.1. Establis	h an evidence-	based comm	nunication	program targe	ting the public for both	human and	animal health	
<ul> <li>1.1.1. Assess public awareness about AMR through:</li> <li>Survey on public awareness of use and misuse of antibiotics.</li> <li>Assign a research team to conduct qualitative (focus group) and quantitative (surveys) data collection.</li> </ul>	Public Awareness Survey	1	NOV 2017	Nationwide	AMR awareness technical committee	100,000	МОН	Increases level of awareness
<ul> <li>Survey on knowledge and attitude toward use and misuse of Antibiotics in livestock.</li> </ul>	Public Awareness Survey	1	NOV 2017	Nationwide	AMR awareness technical committee		MEWA	
1.1.2 Production of Media related materials including documentary on AMR	AMR website	1	NOV 2017	Network	AMR awareness technical committee	70,000	МОН	Number of documentari es produced
1.1.3 Annual awareness campaign during Antimicrobial in response to WHO World Antibiotic Awareness Week	awareness campaign	1	NOV 2017	Nationwide	AMR awareness technical committee	200,000	МОН	Number of participating sectors
1.1.4 Mainstream media engagement	awareness campaign	2	NOV 2017	Nationwide	AMR awareness technical committee	-	МОН	Number of participating TV channels

1.1.5	Applying the tailored nterventions:  2 Award university clubs.	awareness campaign	5	NOV 2017	Nationwide	AMR awareness technical committee	25,000	мон	Number of participating universities
	<ul><li>3 Work with MOH and launch the Public Health Champion program.</li><li>4 Work with MOE on national curriculum to include the AMR topic.</li></ul>	awareness campaign	2	NOV 2017	Nationwide	AMR awareness technical committee	10,000	мон	increased awareness of AMR among school students
		awareness campaign	1	NOV 2017	Nationwide	AMR awareness technical committee	20,000	МОЕ	
						_			fo lo a.t.la
	tegic intervention 1.2. Esta	ablish an evid	ence-based	d public co	ommunicatio	n program targeting	the healthc	are provide	rs for both
hum	an and animal health.  Awareness program will be prepared for healthcare providers for both in human and animal health	awareness program	1	NOV 2017	Nationwide	National AMR awareness technical committee	200,000	MOH + MEWA	Number of participating healthcare providers for both in human and animal health
<b>hum</b> 1.2.1	an and animal health.  Awareness program will be prepared for healthcare providers for both in human and animal health	awareness program	1	NOV 2017	Nationwide	National AMR awareness technical committee	200,000	MOH + MEWA	Number of participating healthcare providers for both in human and animal health

2.1.2 AMR E – Learning educational program	Program	1	Jan 2018	Nationwide	GDIPC	300,000	SCFHS	Prepared by committees and approved by Saudi Commission
2.1.3 AMR revised and approved educational programs_in health care facilities	Program	1	Nov. 2017	Nationwide	National AMR (Stewardship & technical committee)	210,000	МОН	Prepared by MOH
Strategic intervention 3.1. Estab	lish a nationa	l coordinat	on structi	ure for survei	llance of AMR			
3.1.1 National coordinating committee with appropriate mandate and terms of reference and a focal point	National coordinatin g committee	1	JAN201 7	Nationwide	Lab surveillance technical committee.	-	-	Committee formation
Strategic intervention 3.2. Desig	nate and deve	elop refere	nce micro	biology labora	atory facilities to coor	dinate effec	tive epidemi	ologically
surveillance of antimicrobial res	istance							
3.2.1 Seven CAP accredited. Laboratories were designated to collect the antimicrobial resistance data for the last five years. Riyadh: (KAMC-Riyadh, King Faisal Specialist Hospital & Research Center, KFMC, and King Khaled University Hospital); Eastern Province: King Fahd University hospital in Khobar; Western Province: King Abdulaziz University Hospital.	Seven CAP accredited hospital	Retrospe ctive 5 years Antibiogr am report	Nov 2017	Assigned CAP- accredited labs	Lab surveillance technical committee.	-	-	Percentage of resistant organisms

3.2.2 Twenty-four MOH laboratories Antibiogram from various regions of the kingdom.	24 MOH labs	Biannual Antibiogr am reports	March 2017	MOH labs	Lab surveillance technical committee.	-	МОН	Percentage of resistant organisms
3.2.3 Utilizing Point of care tests	National Lab	3	DEC 2017	Nationwide	Lab surveillance technical committee	2,000,000	МОН	total number of centers UTILIZING point of care tests
Strategic intervention 3.3. AMF			s in huma					
3.3.1. AMR surveillance Sentinel sites from different regions are selected  KAMC-Riyadh, King Faisal Specialist Hospital & Research Center, KFMC, and King Khaled University Hospital); Eastern Province: King Fahd University hospital in Khobar; Western Province: King Abdulaziz University Hospital.  King Abdulaziz — Jeddah  King Fahd Hospital — Jeddah  Dammam Medical Complex - eastern region  Assir Central Hospital	National Lab	12	June 2017	Nationwide	Lab surveillance technical committee	225,000	MOH	Percentage of AMR priority pathogens resistance

Assir • King Khaled Hospital – Tabouk								
Strategic intervention 3.4. AMR	surveillance S	entinel Site	es in anima	al				
3.4.1 Six Sentinel sites for surveillance of infections caused by AMR pathogens: Riyadh. Al-ahssa Al-Dammam Jeddah Assir Al-Kharj	AMR animal sentinel sites	6	June 2017	Nationwide	Lab surveillance technical committee	100,000	MEWA	Percentage of resistance of priority pathogens in animals
3.4.2. Surveillance for detection of salmonella, campylobacter and total bacterial count in poultry in all regions of Kingdom	MEWA report	1	Dec. 2017	Nationwide	Lab surveillance technical committee	100,000	MEWA	Percentage of resistance
Strategic intervention 3.5. Deter	mine the count	ry priority m	nicroorgani	sms with mech	nanisms of resistance fo	or AMR surve	illance and ad	apt and apply
WHO model systems for antimicro	bial resistance	surveillance	(GLASS)					
3.5.1 WHO priority pathogens including (S. aureus, E. coli, K. pneumoniae MRSA, VRE, Non-Fermentative GNB Acinetobacter, and pseudomonas)	Number of isolated priority pathogens	Number of isolates for each pathogen	Dec. 2017	Human sentinel sites	Lab surveillance technical committee	-	МОН	Percentage of resistance of each pathogen
3.5.2 GLASS protocol was endorsed to laboratories during a workshop (10 Labs) and includes age and sites in	Number of labs endorsed in GLASS	10	March 2017	MOH labs	Lab surveillance technical committee	70,000	МОН	Number of labs implementing

	the upcoming data.								GLASS protocol
	egic intervention 3.6. Estab	lishment of sy	stems IT fo	r monitor	ing antimicrob	pial and link all sentine	l sites to the	national c	enter for
	rsis and reporting.		T	1	1	T	T	T	•
3.6.1	Working on software	Number	20 MOH	Oct	Sentinel	Lab surveillance	225.000	MOH	Number of
	to link Designated	of labs		2017	sites	technical			labs
	sentinel to national	linked to				committee			reporting
	lab to improve	software							through the
	reporting analysis								software
Strate	egic intervention 4.1. Desig	nate a nationa	al reference	laborato	ry for AMR su	rveillance	•	1	<u> </u>
4.1.1	The National lab will	National	1	DEC	NATIONAL	NATIONAL LAB	1,500,000	МОН	percentage of
	assume responsibility	Lab		2017	LAB				referral of
	for AMR lab in future.								isolates of
	Currently, AMR								AMR to
	sentinel sites labs will								national AMR
	perform required AMR								lab
	testing and reporting								
Strate	egic intervention 4.2. Traini	ing workshops	for microb	piologist a	nd laboratory	technicians		_	
4.2.1	Plan for series training,	Training	5	NOV	Nationwide	Lab surveillance	70,000	MOH	Number of
	workshops will be	course		2017		technical committee			trained staff
	formulated for								
	Microbiology doctors								
	and lab technicians for								
	all hospitals> 150 beds	<u> </u>							
	egic intervention 5.1. Creat	e a formal org	ganizationa	l structure	e to ensure pr	oper development an	d use of infe	ction prev	ention and
	ol policies and strategies			2047		100		1	A
	. IPC Organizational	Organizatio	1	2017	Nationwide	IPC technical	0	МОН	Number of
struci	ture has been established	nal				committee			hospitals
		structure							have IPC
									organizational
<b>543</b>	Commence	6	1	2047	NI-11- 11	IDC to decide	60.006	14011	structure
	. Core component has	Core	1	2017	Nationwide	IPC technical	60,000	МОН	Number of
	established and	component				committee			hospitals
aistril	buted								implementing

								core component
5.1.3. Infection control national manual distributed to all health care regions	IPC manual	1	2017	Nationwide	IPC technical committee	60,000	МОН	Number of hospitals implementing IPC manual
5.1.4. IC Auditing tool program	Auditing tool	1	2017	Nationwide	IPC technical committee	60,000	МОН	Auditing tool Scoring
5.1.5. Hand hygiene campaign	HH campaign	1	2017	Nationwide	IPC technical committee	200,000	МОН	Number of participating sectors
Strategic intervention 6.1. Creat					oper development a	nd use of infe	ection prever	ntion and
control policies and strategies (in		nd animal	husbandr	y)				
6.1.1. Write and approve Infection Control Guideline in animal health by KSA MEWA	IPC Guideline	1	June 2017	Nationwide	IC technical committee	60,000	MEWA	Number of Vet Clinics implementing guidelines
Strategic intervention 6.2. Include	de hygiene an	d infection	preventio	n and contro	l as core (mandatory)	content in t	raining and e	<u> </u>
veterinary professionals				_				
6.2.1. MEWA plans for Infection control training	Training program	1	June 2017	Nationwide	IPC technical committee	100,000	MEWA	Number of trained staff
Strategic intervention7.1. Promo	te personal h	ygiene by	social mol	oilization and	behavioral change ac	tivities		
7.1.1. Estimate knowledge of personal hygiene in different social groups as a basis for the social mobilization campaigns	Awareness social hygiene campaigns	1	June 2017	Nationwide	GDIPC	200,000	МОН	Increased level of public awareness about personal hygiene
Strategic intervention 8.1. Stren	gthen the pha	rmaceutica	al supply o	hain, includir	ng the procurement, s	supply and m	anagement s	system
8.1.1. Establish a quality management system for the supply of medicines, covering storage, transport, expiry date, etc.	Chain of supply	1	June 2017	Nationwide	Drug economy and technical research committee	50,000,000	SFDA	no of implemented system

9.1.1. Plan for series training,	Training	3	DEC	Nationwide	МОН	210,000	МОН	Number of
antimicrobial stewardship	program		2017					trained staff
programs workshops will be								
formulated in all healthcare								
facilities > 150 beds								
Strategic intervention 9.2. Awa	reness and Edu	ucation or	stewards	hip for Health	care facilities & veter	inary praction	ce	
9.2.1. Target selected hospitals	educationa	5	Nov	Nationwide	Stewardship	350,000	MOH	Number of
ased on bed capacity from each	l activities		2017		technical committee			implemented
egion of the kingdom:								activities
L- Antibiotic Awareness week								
2-Training Activities in ASP								
9.2.2 To consider	standardize	1	June	Nationwide	Stewardship	100,000	МОН	Number of
standardized educational	d		2017		technical committee			staff using
material or electronic tool	educationa							electronic
	l tool							tool
Strategic intervention 9.3. Guid	elines and orde	er sets						
9.3.1. Development,	Guidelines	1	June	Nationwide	Stewardship	60,000	МОН	Number of
wareness & Implementation			2017		technical committee			hospitals
of empiric antimicrobial								implementing
guidelines for treatment of								guidelines
community & healthcare								
associated infection to 20								
MOH hospitals.								
9.3.2 Integrating those	Electronic	1	June	Nationwide	Stewardship	100,000	МОН	Number of
guidelines into electronic	Guidelines		2017		technical committee			hospitals
nealth records whenever								linked to
possible.								electronic
			1.		0. 11:		1	guidelines
9.3.3 Standardizing Surgical	Antibiotic	1	June	Nationwide	Stewardship	60,000	МОН	Number of
Antibiotic Prophylaxis through	surgical		2017		technical committee			hospitals
preset order sheets in 20	prophylaxis							implementing
selected MOH hospitals.	Guidelines							surgical
								prophylaxis

Strategic intervention 9.4. Clinical (	Care Standard	ls "bundle"	impleme	ntation				
9.4.1. hospitals (>150 beds should apply "MOH-approved" stewardship bundles/ best practices to optimize prescribing practices  Strategic intervention 9.5. Manda	Steward- ship bundles	1  ship imple	Dec 2017 mentation	Nationwide	Stewardship technical committee  AHI accredited hospita	100,000	МОН	Number of MOH hospitals applying stewardship bundles
9.5.1. Communicate with CBAHI to include ASP in the requirements for accreditation/ reaccreditation."			June 2017	Nationwide	Stewardship technical committee	-	СВАНІ	
Strategic intervention 9.6. Requesti	. •					T		
9.6.1. 5 Antibiotics, 5 MDROs	- DOT per 1000 patient days - Duration of empiric antibiotics therapy more than seven days - Prevalence and trend of CDI		April 2017	Nationwide	Stewardship technical committee	-	МОН	DOT per 1000 patient days - Duration of empiric antibiotics therapy more than seven days -Prevalence and trend of CDI
Strategic intervention 9.7. Postgrad		l	•				1	
9.7.1 Communication with Saudi Commission for Health Specialties to add to Infection control module Stewardship component; it can be an online module as a prerequisite for enrollment in all medical,	Online IC module stewardshi p	1	Jan 2018	Nationwide	GDIPC	100,000	SCFHS	Number of staff linked to Online IC module stewardship

nursing, paramedical, and								
Pharmacy residency programs."								
Strategic intervention 9.8. Building	<b>Capacity: Trai</b>	ning Clinica	l Pharmacis	ts and ID Fello	ows			
9.8.1 Antimicrobial Stewardship training programs	training program	1	Jan 2018	Nationwide	Stewardship technical committee	500,000	SCFSH	number of candidates joining the asp training program
Strategic intervention 9.10. Antimic	robial Stewar	dship Resea	rch					
9.10.1National Point Prevalence Survey on antimicrobial consumption & resistance in line with Global PPS -Multicenter study on the impact of implementation of stewardship on length of stay & cost saving  Strategic intervention 10.1. Rest	PPS study	1 tically impo	June 2017 ortant anti	Nationwide  microbials fo	Stewardship technical committee	250,000	MOH	Antimicrobial consumption rate
10.1.1. Ongoing surveillance of		1	Jan		Stewardship	250,000	MEWA	Antibiotic
antibiotics consumed in food production animals and avoiding the following antimicrobial classes: Quinolones, 3rd and 4th generation cephalosporins, macrolides, ketolides, and glycopeptides	Surveillance program		2018	Nationwide	technical committee	·		consumption in food production
Strategic intervention Economic	11.1. impact	assessmen	t and burd	en of antimic	robial resistance			
11.1.1. Study the cost and economic burden of AMR in Humans	Research study in human	1	June201 7	Nationwide	Drug Economy and technical research committee	250,000	МОН	Percentage of AMR and cost of antibiotics
11.1.2. Study the cost and economic burden of AMR in animals.	Research study in human	1	Oct 2017	Nationwide	Drug economy and research technical committee	250,000	MEWA	Percentage of AMR and cost of antibiotics

Part III:

Monitoring and evaluation plan

# Monitoring and evaluation plan

Planning element (activity linked to the strategic plan)	Indicator	Purpose	Calculation	Frequency of data collection	Data source	Method	Baseline
1.1.1 Assess public awareness about AMR through:  o Survey on public awareness of use and misuse of antibiotics.  Assign a research team to conduct qualitative (focus group) and quantitative (surveys) data collection.	Increases level of awareness	M&E of input	No. of participating in the survey / total No. groups to target	Annually	AMR awareness committee	Baseline survey and	What measured in baseline survey
2.1.1. Include AMR and related topics in undergraduate curricula for professionals in human and animal health, the food industry and agriculture professionals.	number of approved curricula available for undergraduate	M&E of input	No. of curricula / No. undergraduate groups to target	Annually	MOE	Baseline survey and post- interventio n survey	What measured in baseline survey
2.1.2. AMR E – Learning educational program	approved PROGRAM by Saudi Commission	M&E input	of No., of curricula / No. undergraduate groups to target input	Annually	GDIPC	SCHF	Number of trained staff

3.2.1. Seven CAP accredited.  Laboratories were designated to collect the antimicrobial resistance data for the last five years. Riyadh: (KAMC-Riyadh, King Faisal Specialist Hospital & Research Center, KFMC, and King Khaled University Hospital); Eastern Province: King Fahd University hospital in Khobar; Western Province: King Abdulaziz University Hospital.	Percentage of retrospective AMR in hospitals	M&E of input and Output	No. of AMR isolates / Total No of isolates target	Annually	Lab surveillance technical committee.	Lab surveillance technical committee report.	Total no of isolates
3.2.6. Utilizing "Point of care tests	total number of centers utilizing point of care tests	M&E of input	No of centers utilizing point of care tests / total no of targeted centers		Lab surveillance technical committee.	Lab surveillance technical committee report.	Centers utilizing point of care testing currently
<ul> <li>3.3.1 AMR surveillance Sentinel sites from different regions are selected</li> <li>KAMC-Riyadh, King Faisal Specialist Hospital &amp; Research Center, KFMC, and King Khaled University Hospital); Eastern Province: King Fahd University hospital in Khobar; Western Province: King Abdulaziz University Hospital.</li> <li>King Abdulaziz – Jeddah</li> <li>King Fahd Hospital – Jeddah</li> </ul>	Percentage of resistance of priority pathogens in animals	M&E of input And output	No of AMR Isolate /Total No of isolates of priority pathogens	Annually	AMR lab surveillance committee	AMR surveillance program implementa tion report	Total No of AMR isolates

<ul> <li>Dammam Medical         Complex - eastern region</li> <li>Assir Central hospitals Assir</li> <li>King Khaled Hospital – Tabouk</li> </ul>							
34.1 Six Sentinel sites for surveillance of infections caused by AMR pathogens:  Riyadh.  Al-Ahssa  Al-Dammam  Jeddah  Assir  Al-Kharj	Percentage of resistance of priority pathogens in animals	M&E of input And output	No of AMR Isolate /Total No of isolates of priority pathogens	Annually	AMR lab surveillance committee	AMR surveillance program implement ation report	Total number of AMR isolates
4.2.1. Plan for series training, workshops will be formulated for Microbiology doctors and lab technicians for all hospitals> 150 beds	Number of trained staff	M&E of input	No of trained staff/total No of target staff	Annually	AMR lab surveillance committee	AMR surveillance program implement ation report	Current number of trained staff of target group
5.1.4. IC Auditing tool program	Auditing tool Scoring	M&E of input and output	No. of hospitals /total no. Health care organizations	Annually	IPC technical committee	IPC technical committee report	Number of participating health care organization
5.1.5. Hand hygiene campaign	Number of participating	M&E of input	No. of participating organization	Annually	IPC technical committee	IPC technical committee	Number of participating

	health care organization		/total no. Health care organizations		report	report	health care organization
6.1.1. Write and approve Infection Control Guideline in animal health by KSA MEWA	Number of Vet Clinics implementing Guidelines	M&E of input	No. of Number of vet clinics participating /total no. VET clinics	Annually	IPC technical committee report	IPC technical committee report	Number of participating vet clinics
6.2.1. MEWA plans for Infection control training	Number of trained staff	M&E of input	Some trained staff/no. Of target group	Annually	IPC technical committee	IPC technical committee report	Number trained staff of target group
7.1.1. Estimate knowledge of personal hygiene in different social groups as a basis for the social mobilization campaigns	Increased level of public awareness about personal hygiene	monitori ng and evaluatio n of outcome	Awareness scores stratified by target group (composite)	Annually	Baseline survey report the post-	Awareness survey report	Baseline survey report
					interventi on survey report		
8.1.1. Establish a quality management system for the supply of medicines, covering storage, transport, expiry date, etc.	No. of implemented system	M&E of output	No. of implemented system/ NO health care of organization	Annually	Drug economy and technical research committee	supply chain report	NA
9.1.1. Plan for series training, antimicrobial stewardship programs workshops will be formulated in all healthcare facilities > 150 beds	Number of trained staff	M&E of input	No of trained staff/total NO of targeted staff	Annually	Stewardshi p technical committee	Stewardshi p technical committee report	No. training staff

9.2.1. Target selected hospitals based on bed capacity from each region of the kingdom:  1- Antibiotic Awareness week  2- training actives in ASP	Number of implemented activities	M&E of input	No of trained staff/total NO of targeted staff	Annually	Stewardshi p technical committee	Stewardshi p technical committee report	No training staff
9.3.1. Development, awareness & Implementation of empiric antimicrobial guidelines for treatment of community & healthcare associated infection to 20 MOH hospitals.	Number of hospitals implementing guidelines	M&E of input	Number of hospitals implementing guidelines/ total no. of target hospitals	Annually	Stewardshi p technical committee report.	Stewardshi p technical committee' s survey.	No hospitals implementing guidelines in the baseline survey
9.3.3 Standardizing Surgical Antibiotic Prophylaxis through preset order sheets in 20 selected MOH hospitals.	Number of hospitals implementing surgical prophylaxis guideline	M&E of input	Number of hospitals implementing guidelines/ total no. of target hospitals	Annually	Stewardshi p technical committee report.	Stewardshi p technical committee survey	No standardized surgical antibiotic prophylaxis preset order sheets
9.10.1. National Point Prevalence Survey on antimicrobial consumption & resistance in line with Global PPS -Multicenter study on the impact of implementation of stewardship on length of stay & cost saving	Antimicrobial utilization rate	M&E of input and output	1- DOT per 1000 patient days 2- Duration of empiric antibiotics therapy more than seven days	Annually	stewardshi p technical committee survey	Stewardshi p technical committee. Survey	antimicrobial utilization report
11.1.1. Study the cost and economic burden of AMR in Humans.	The cost of management	M&E of output	Composite	annually	Drug economy	Drug economy	No previous research

	of AMR				committee	committee	
	patient				report.	report.	
11.1.2. Study the cost and economic burden of AMR in the animal.	The cost of AMR in animals	M&E of output	Composite	annually	drug economy committee report.	Drug economy committee report.	No previous research

## References

- 1. World Health Organization. Global Action Plan on Antimicrobial Resistance. WHO. Geneva (CH): 2015. Available from: <a href="http://www.who.int/drugresistance/global-action-plan/en/">http://www.who.int/drugresistance/global-action-plan/en/</a>
- 2. Global Health Security agenda. Country assessment tool. 2015
- 3. Zowawi HM, Forde BM, Alfaresi M, Alzarouni A, Farahat Y, Chong TM, et al. Stepwise evolution of pandrug-resistance in *Klebsiella pneumoniae*. Sci Rep. 2015;5:15082.
- 4. Zowawi HM, Balkhy HH, Walsh TR, Paterson DL. β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev. 2013;26:361–380.
- 5. Al-Obeid S, Jabri L, Al-Agamy M, Al-Omari A, Shibl A. Epidemiology of extensive drug-resistant *Acinetobacter baumannii* (XDRAB) at Security Forces Hospital (SFH) in Kingdom of Saudi Arabia (KSA) J Chemother. 2015;27:156–162.
- 6. Zowawi HM, Sartor AL, Sidjabat HE, Balkhy HH, Walsh TR, Al Johani SM, et al. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* isolates in the Gulf Cooperation Council States: dominance of OXA-23-type producers. J Clin Microbiol. 2015;53:896–903.
- 7. Shibl AM, Memish ZA, Kambal AM, Ohaly YA, Ishaq A, Senok AC, et al. National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia. J Chemother. 2014;26:13–18
- 8. Leangapichart T, Gautret P, Griffiths K, Belhouchat K, Memish Z, Raoult D, et al. Acquisition of a high diversity of bacteria during Hajj pilgrimage, including *Acinetobacter baumannii* with blaOXA-72, and *Escherichia coli* with blaNDM-5 carbapenemases. Antimicrob Agents Chemother. 2016 pii: AAC.00669-16
- 9- Antibiogram report 2015, GDIPC, MOH, KSA